Figure 6.
Inhibition of PKCβ prevents hemorrhagic transformation after delayed tPA treatment. (A) PDGFiCre+ mice and PDGFiCre+; S490AOCC+/+ mice were subjected to MCAO and then treated intravenously with either PBS or tPA (10 mg/kg) 5 hours after MCAO. (B) The volume of hemorrhage was quantified from serial brain sections 72 hours after MCAO. (C) Mice were subjected to MCAO; 1 hour (light blue bars) or 5 hours (green bars) later, animals were treated with vehicle (Veh) or PKCβ inhibitor (PKCβi; 10 mg/kg) daily for 3 days. Delayed tPA thrombolysis was performed 5 hours after MCAO, and brains were analyzed at 72 hours after MCAO. (D) Hemorrhage volume was measured 72 hours after MCAO. One-way analysis of variance followed by a Holm-Šídák post hoc test was used for comparison of ≥3 groups; a t test was used for comparison between 2 groups. ***P < .001, ****P < .0001. ns, nonsignificant.

Inhibition of PKCβ prevents hemorrhagic transformation after delayed tPA treatment. (A) PDGFiCre+ mice and PDGFiCre+; S490AOCC+/+ mice were subjected to MCAO and then treated intravenously with either PBS or tPA (10 mg/kg) 5 hours after MCAO. (B) The volume of hemorrhage was quantified from serial brain sections 72 hours after MCAO. (C) Mice were subjected to MCAO; 1 hour (light blue bars) or 5 hours (green bars) later, animals were treated with vehicle (Veh) or PKCβ inhibitor (PKCβi; 10 mg/kg) daily for 3 days. Delayed tPA thrombolysis was performed 5 hours after MCAO, and brains were analyzed at 72 hours after MCAO. (D) Hemorrhage volume was measured 72 hours after MCAO. One-way analysis of variance followed by a Holm-Šídák post hoc test was used for comparison of ≥3 groups; a t test was used for comparison between 2 groups. ***P < .001, ****P < .0001. ns, nonsignificant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal